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Background: To date the IMSI procedure represents the only real-time and unstained method available to discard
spermatozoa with ultrastructural defects. Several studies demonstrated that IMSI provides positive results in couples
with severe male factor infertility or repeated ICSI failures. Aim of this pilot study is to evaluate the differences
between IMSI and ICSI in terms of IVF outcomes in an unselected infertile patient population.
Methods: Three hundred and thirty-two couples were analyzed: 281 couples underwent conventional ICSI
procedure and 51 underwent IMSI technique.
Results: No statistically significant differences were found between implantation rate (ICSI: 16,83%; IMSI: 16,67%),
fertilization rate (ICSI: 77,27%; IMSI: 80,00%) and pregnancy rate (ICSI: 25,30%; IMSI: 23,50%). Both groups were
comparable when considering live birth rate (ICSI: 11,39%; IMSI:13,72%), ongoing pregnancy rate (ICSI: 7,47%; IMSI:
5,88%) and miscarriage rate (ICSI: 17,78; IMSI: 5,26%). The subgroup analyses did not show a statistical difference
between ICSI and IMSI neither in male factor infertility subgroup nor in patients with more than one previous ICSI
attempt. A trend towards better laboratory and clinical outcomes was detected in the male factor infertility
subgroup when IMSI was applied.
Conclusions: Our preliminary results show that the IMSI technique does not significantly improve IVF outcomes in
an unselected infertile population.
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Introcytoplasmic sperm injection (ICSI) represents the
recommended treatment in many cases of infertility and is
characterized by a pregnancy rate per cycle of about 30%
[1]. The power of ICSI as a tool to overcome fertilization
failures in IVF procedures has led to a first common ac-
ceptance by embryologists that morphology of the selected
sperm for injection was of secondary importance [2]. The
selection process preceding the micro-injection of a motile,
normal-looking spermatozoon into the oocyte’s cytoplasm
is usually performed under a low magnification (×200/400)
that could be responsible for the underestimation of* Correspondence: roberto.marci@unife.it
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reproduction in any medium, provided the orpossible subtle sperm organellar malformations. A sperm-
atozoon classified as “normal” after a morphologic evalu-
ation performed at low magnification could carry relevant
ultra-structural defects that could interfere with fertilization
process and embryo development. In 2002 Bartoov et al.
developed a method of human spermatozoa evaluation
called “motile sperm organelle morphology examination”
(MSOME) [3]. It permits spermatozoa observation at high
magnification (>6000x) compared to the 200-400x observed
by conventional ICSI using an inverted microscope
equipped with Normarski interference contrast optics. Ap-
plication of this method to patients undergoing conven-
tional IVF/ICSI has led to the development of the
intracytoplasmatic morphologically selected sperm injec-
tion (IMSI, Figure 1).
Aim of this pilot study is to evaluate the differences
between IMSI and ICSI in terms of IVF outcomes in an
unselected infertile patient population.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Live spermatozoa observed under conventional ICSI conditions (A) and IMSI magnification (B, C, D). Shape and presence of
vacuoles can be clearly observed in B. A vacuole-free spermatozoon is shown in C.
Marci et al. Reproductive Health 2013, 10:16 Page 2 of 5
http://www.reproductive-health-journal.com/content/10/1/16Methods
From January 2009 to March 2012, 332 couples were an-
alyzed. Couples were divided into two groups by using a
randomized computer-generated list as follows: 281 cou-
ples underwent conventional ICSI procedure and 51
underwent IMSI technique. All cycles were performed
with fresh ejaculated spermatozoa. Patients who required
the use of cryopreserved or surgically retrieved semen
were excluded from this study. This work has been car-
ried out in accordance with The Code of Ethics of the
World Medical Association (Declaration of Helsinki) for
experiments involving humans. The study was approved
by our clinical board. All patients in both groups were
enrolled after signing a written informed consent.
All women were stimulated using 150–375 IU of r-FSH
(Gonal-FW, Merck Serono, Switzerland; PuregonW, MSD,
Switzerland) from d-2 of the menstrual cycle, followed by
daily dose of GnRH antagonist Ganirelix or Cetrorelix
(GanirelixW 0.25 mg, OrgalutranW, MSD, Switzerland;
CetrotideW 0.25 mg, Merck Serono, Switzerland) starting
from d-5 of the ovarian stimulation until the day of hCG
injection. In order to evaluate the ovarian response E2
was monitored and transvaginal ultrasounds (US) were
performed every 2–3 days. In both groups ovulation
triggering was achieved by using a subcutaneous injec-
tion of 10000 IU of human chorionic gonadotropin
(PregnylW, MSD, Switzerland) as soon as at least 2 fol-
licles of at least 17 mm were detectable on US scan.
Oocyte retrieval was performed by transvaginal aspir-
ation 36 hours after hCG administration. Embryo
transfers (ETs) were performed 48 hours after oocyte
retrieval using a K Jet catheter, Prince catheter, Prince
Medical, France. The luteal phase was supported by
200 × 2 mg/day of micronized vaginal progesterone
(UtrogestanW, Vifor SA, Switzerland). Serum hCG level
was measured 14 days after ET. Clinical pregnancies
were confirmed with US scans 28–35 days after ET by
the presence of gestational sac and fetal heart activity.
IMSI requires a high magnification inverted micro-
scope (600-1000x). A high magnification objective lens
(60x) in combination with Hoffman’s contrast on astandard injection microscope (Olympus IX71) was used.
Using a 1.6x magnification enhancer a total magnification
of 960x can be achieved. Glass-bottomed dishes are re-
quired for the specimen observation in order to achieve
the best optical quality associated with the real-time
digital image enhancement (Octax CytoScreen TM sys-
tem, Medical Technology Vertriebs-GmbH, Germany),
the setup provides an excellent image quality with a total
on-screen magnification of about 5400x. Analysis and se-
lection of motile spermatozoa were performed according
to the MSOME criteria described by Bartoov et al. [3].
Laboratory and clinical outcomes were evaluated in the
two groups. Subgroups analyses were then performed
according either to the presence of a male infertility factor
or to the number of previous ICSI attempts.
Results are presented as mean ± standard deviation.
Differences in variables were statistically analyzed with
the nonparametric Wilcoxon’s signed rank test, Student’s
t test and χ2 test, as appropriate. A P value of less than
.05 was considered statistically significant.
Results
The characteristics of the studied population (Table 1)
were similar in both IMSI and ICSI groups when consid-
ering women’s age, number of previous ICSI treatment
failures, mean number of retrieved and injected oocytes
and semen parameters (evaluated in accordance to
WHO criteria 2010). The majority of couples had male
factor infertility in both ICSI and IMSI groups. Both the
mean age of male partners and the percentage of pre-
pared sperm motility were statistically different but nei-
ther of these parameters influences the outcome of a
microinjection technique, according to the published lit-
erature [4-6]. No statistically significant differences were
found between implantation rate, fertilization rate and
pregnancy rate. Both groups were comparable when
considering live birth rate, ongoing pregnancy rate and
miscarriage rate. In the IMSI group fertilization rate and
live birth rate were slightly higher and the miscarriage
rate tended to be lower when compared to the ICSI
group, although no statistical significance was found.
Table 1 Main characteristics of the patients and clinical-







N° of cycles 281 51
Women age at Pickup 34,98 3,19 35,65 2,98 0,15
Men age at Pickup 37,61 5,47 39,51 5,23 0,02
N° of ICSI attempts 1,61 0,88 1,55 0,87 0,68
Causes of infertility (%):
• Tubal factor 8.5 9.8
• Ovulatory 5.3 1.9
• Endometriosis 7.5 7.8
• Male factor 36.6 39.2
• Multiple factors 20.9 19.6
• Unexplained 21 21.6




23,58 29,34 27,75 32,29 0,39
Native sperm motility
rate (%)




16,12 23,94 21,1 21,46 0,14
Prepared sperm
motility (%)
54,43 24,62 60,16 16,95 0,04
2 pronuclei day 1 6,27 3,72 6,59 3,57 0,57
N° of transferred embryos 1,86 0,38 1,87 0,33 0,85
Implantation rate (%) 16,83 16,67 0,97
Fertilization rate (%) 77,27 80,00 0,22
Pregnancy rate (%) 30,96 33,33 0,74




Miscarriage rate (%) 17,78 5,26 0,17
Table 2 Comparison between IMSI and ICSI groups according
of previous ICSI attempts
No male factor infertility Male factor infertility
ICSI IMSI p-value ICSI IMSI p-value
FR 80.64% 80.54% NS 73.03% 79.17% NS
IR 17.87% 14.29% NS 16.13% 18.18% NS
PR 35.40% 27.78% NS 28.07% 37.14% NS
MR 9.73% 11.11% NS 1.17% 5.7% NS
LBR 11.80% 5.55% NS 11.11% 20% NS
FR: Fertilization Rate; IR: Implantation Rate; PR: Pregnancy Rate; MR: Miscarriage Rat
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tical difference was reported neither in male factor infer-
tility subgroup nor in patients with more than one
previous ICSI attempt. A trend towards better laboratory
and clinical outcomes was detected in the male factor
infertility subgroup when IMSI was applied. When pa-
tients with more than one previous ICSI failure were
treated with IMSI a significantly higher fertilization rate
was achieved (84.10% versus 76.55%). However, in the
same subgroup was reported a trend towards lower im-
plantation rate, pregnancy rate and live birth rate as well
as higher miscarriage rate. Live birth rate reached the
statistical significance in the subgroup of patients treated
with IMSI with one or no previous ICSI failures.
Discussion and conclusions
Several studies demonstrated a positive correlation be-
tween optimal sperm morphology evaluation and ICSI
outcomes improvement. De Vos et al. [7] evaluated the
impact of individual sperm morphology on ICSI out-
come (fertilization, embryo development and implant-
ation rate). This study was performed by using an
inverted light microscope and sperm cells were classified
as normal or abnormal in accordance to Kruger criteria
[8]. The authors demonstrated that the injection of an ab-
normal spermatozoa was associated to a significantly
lower fertilization, implantation and pregnancy rate when
compared to ICSI cycles performed by injecting a sperm-
atozoa with apparently normal morphology. The low mag-
nification and resolution of the microscope used for the
morphology assessment represented the main limitation
of this study. At the present time the ICSI technique is
performed under a low magnification (×200/400) that
could be responsible for the underestimation of possible
subtle sperm organellar alterations. Spermatozoa morph-
ology is the best selection criteria for intracytoplasmatic
injection. To date the IMSI procedure represents the only
real-time and unstained method available to discard
spermatozoa with ultrastructural defects. Indeed, most of
the enzymatic or genetic tests currently available cannot
be performed on a viable, unfixed, spermatozoa. The de-
tection of large nuclear vacuoles at high magnificationto the presence of male factor infertility and the number
>1 ICSI attempt ≤ 1 ICSI attempt
ICSI IMSI p-value ICSI IMSI p-value
76.55% 84.10% < 0.05 77.75% 78.12% NS
17.35% 6.2% NS 16.44% 22.41% NS
30.57% 15.79% NS 31.25% 43.75% NS
10.7% 5.2% NS 10.62% 12.5% NS
19% 10% NS 9.4% 21.87% < 0.05
e; LBR: Live Birth Rate; NS: not significant.
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It is widely accepted that DNA integrity plays an import-
ant role in the fertilization process and in the development
and implantation of embryos [9,10]. Furthermore,
Vanderzwalmen et al. [11] reported a negative influence of
spermatozoa with large nuclear vacuoles in the head on
the capability of embryos to develop to the blastocyst
stage.
Antinori et al. [12] pointed out the need to increase
the efficiency of micro-insemination techniques espe-
cially in those countries, such as Italy, where the law
limits the number of fertilizable oocytes. Several studies
demonstrated that IMSI provides positive results in cou-
ples with severe male factor infertility or repeated ICSI
failures [3,12,13]. In all these studies the clinical preg-
nancy rate was noticeably improved in the IMSI group.
Moreover, the IMSI group result was associated with a
lower abortion rate. Besides, other studies do not show
any statistical significant improvement in the clinical
outcome. Oliveira et al. [14] report no significant differ-
ences between fertilization rate, implantation rate and
pregnancy rate when comparing the two procedures, al-
though a trend toward lower miscarriage rate and better
ongoing pregnancy rate and live birth rate was found in
the IMSI group.
Balaban et al. [15], recently analyzed in a prospective
randomized study the clinical differences between IMSI
and ICSI procedures in an unselected population. To the
best of our knowledge, the study mentioned above is the
only one in which the population was not selected nei-
ther for the presence of a severe male factor infertility
nor for a history of repeated previous failed ICSI at-
tempts. IMSI did not provide any significant improve-
ment in the clinical outcome compared to ICSI.
However, trends for higher rates of implantation (28.9%
versus 19.5%), clinical pregnancy (54.0% versus 44.4%)
and live births (43.7% versus 38.3%) were found in the
IMSI group. The second aim of the study was to verify
whether better results were achieved when the iMSI pro-
cedure was applied to the subgroup of male factor infer-
tility. A significantly higher implantation rate was found
in IMSI group (29.6% versus 15.2%). The authors also
reported a slight but not significant improvement in live
birth rate (36.8% versus 28.2%).
In accordance to Balaban et al., our preliminary results
came out to be similar in the two groups, suggesting that
IMSI does not significantly improve IVF outcomes in an
unselected randomized infertile population. As shown
by the subgroup analysis, IMSI did not prove superior to
ICSI in terms of laboratory and clinical results, even
though a positive trend for better fertilization, implant-
ation, pregnancy and live birth rates was detected in the
severe male factor infertility subgroup when IMSI was
applied. The data obtained from the analysis of patientswith previous ICSI failures are not consistent with the
results published in other recent studies [3,12,13]. The
reliability of these results is though limited by the small
sample size of this pilot study, emphasizing the need for
further trials on a larger population. Although further
studies in that direction are necessary in order to state
possible advantages of the IMSI procedure in couples
with severe male factor infertility or with repeated fail-
ures after conventional ICSI.
In conclusion, in the last decades ICSI has been widely
used for the treatment of infertility, in particular in the
case of severe male factor infertility. Moreover, in the
light of its high fertilization and pregnancy rates, ICSI
has gradually replaced conventional IVF and it is now
applied as a first-line therapy by many infertility centers.
The innovative IMSI procedure has changed the percep-
tion of how a spermatozoon, suitable for injection, looks
like. To date, the clinical indications are scarce and de-
rived mainly from the medical history of patients. Our
preliminary results show that the IMSI technique does
not significantly improve IVF outcomes in an unselected
randomized infertile population. In particular, the use of
IMSI in unselected patients did not significantly improve
fertilization, implantation and pregnancy rates when
compared to conventional ICSI. Thus, we do not recom-
mend IMSI for non-male factor, normozoospermic pa-
tients or couples addressing to IVF for the first time.
Furthermore, our work did not show a clear effective-
ness of this method in case of severe male factor infertil-
ity or couples with previous ICSI failures.
Considering the limited number of studies on this
topic, the absence of an adequate standardization of the
method and the lack of worldwide accepted selection
criteria, IMSI is far to be considered as a routinely used
ART technique.
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